A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
oleh: Min Zhang, MBBS, Huan Zhou, MM, Dan Liu, MD, PhD, Ruoying Yu, MD, PhD, Jun Chen, MD, PhD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2021-02-01 |
Deskripsi
Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.